Ignite Creation Date:
2024-05-06 @ 11:01 AM
Last Modification Date:
2024-10-26 @ 12:39 PM
Study NCT ID:
NCT03410108
Status:
COMPLETED
Last Update Posted:
2024-05-08
First Post:
2018-01-11
Brief Title:
Phase 2 Study of Brigatinib in Japanese Participants With Anaplastic Lymphoma Kinase ALK-Positive Non-Small Cell Lung Cancer NSCLC
Sponsor:
Takeda
Organization:
Takeda
Conditions & Keywords Data
Conditions:
| Name |
|---|
| ALK-positive Advanced NSCLC |
Keywords:
| Name | View |
|---|---|
| Drug therapy | View |